Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27593166 | 0.85 | SLC6A2 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL13692285 | 0.80 | — | — | |
| SCHEMBL2022682 | 0.80 | — | — | |
| SCHEMBL14478276 | 0.80 | — | — | |
| SCHEMBL29059546 | 0.80 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL309477 | 0.79 | ALDH1A1 (0.40) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL3506512 | 0.77 | ALDH1A1 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9376259 | 0.77 | GFER (0.56) | TAAR1MAOA | |
| SCHEMBL719865 | 0.74 | L3MBTL1 (0.46) | MAOA | |
| SCHEMBL21622787 | 0.73 | RAB9A (0.44) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MERCK & CO., INC. | 2008-08-21 | — | — | US | claimed |
| EP-1807102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND SEXUAL DYSFUNCTION | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006049933-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND SEXUAL DYSFUNCTION | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | claimed |
| CN-116249697-A | Bicycloheptane pyrrolidine orexin receptor agonists | 默沙东有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3924058-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20200282061-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2020167706-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-2879666-B1 | FREE FLOWING, FROZEN COMPOSITIONS COMPRISING A THERAPEUTIC AGENT | TAVAKOLI ZAHRA (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20180264117-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180125979-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20050272810-A1 | Compositions comprising nebivolol | MYLAN INSTITUTION INC. (F/K/A UDL LABORATORIES, INC.) | 2005-12-08 | — | — | US | disclosed |
| WO-2004105694-A2 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004087052-A2 | OIL-CONTAINING, ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION FOR IMPROVED DELIVERY OF A THERAPEUTIC AGENT | LIPOCINE, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040115287-A1 | Hydrophobic active agent compositions and methods | LIPOCINE, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030235595-A1 | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent | LIPOCINE, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030236236-A1 | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | LIPOCINE INC. | 2003-12-25 | — | — | US | disclosed |
| US-5980882-A | A SOLID OR A GEL MEDICINE COMPRISING DEXTROMETHORPHAN, CODEINE, MORPHINE, HYDRCODONE, PSEUDOEPHEDRINE, OR PHENYLPROPANOLAMINE AND COMPLEXED WITH CHELATING AGENT SELECTED FROM EDTA OR A SALT OF EDTA; STORAGE STABILITY | MEDEVA PHARMACEUTICALS MANUFACTURING (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0911039-A2 | Drug-resin complexes stabilized by chelating agents | Medeva Pharmaceutical Manufacturing, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MC4R, MC5R, MC3R | TAAR1 218/4885SLC6A2 203/4885SLC6A4 284/4885 |
| US-20030235595-A1 | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent | LIPA, LIPC, CETP | TAAR1 2789/4885SLC6A2 1083/4885SLC6A4 1594/4885 |
| US-20050272810-A1 | Compositions comprising nebivolol | ADRB1, ADRB3, ADRB2 | TAAR1 1532/4885SLC6A2 217/4885SLC6A4 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.